These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

243 related items for PubMed ID: 25677062

  • 1. NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivo.
    Yang X, Feng Y, Gao Y, Shen J, Choy E, Cote G, Harmon D, Zhang Z, Mankin H, Hornicek FJ, Duan Z.
    Gynecol Oncol; 2015 Apr; 137(1):134-42. PubMed ID: 25677062
    [Abstract] [Full Text] [Related]

  • 2. Nsc23925 prevents the development of paclitaxel resistance by inhibiting the introduction of P-glycoprotein and enhancing apoptosis.
    Yang X, Shen J, Gao Y, Feng Y, Guan Y, Zhang Z, Mankin H, Hornicek FJ, Duan Z.
    Int J Cancer; 2015 Oct 15; 137(8):2029-39. PubMed ID: 25904021
    [Abstract] [Full Text] [Related]

  • 3. Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925.
    Yang X, Yang P, Shen J, Osaka E, Choy E, Cote G, Harmon D, Zhang Z, Mankin H, Hornicek FJ, Duan Z.
    Br J Cancer; 2014 Jun 10; 110(12):2896-904. PubMed ID: 24853187
    [Abstract] [Full Text] [Related]

  • 4. Synthesis and evaluation of (2-(4-methoxyphenyl)-4-quinolinyl)(2-piperidinyl)methanol (NSC23925) isomers to reverse multidrug resistance in cancer.
    Duan Z, Li X, Huang H, Yuan W, Zheng SL, Liu X, Zhang Z, Choy E, Harmon D, Mankin H, Hornicek F.
    J Med Chem; 2012 Apr 12; 55(7):3113-21. PubMed ID: 22400811
    [Abstract] [Full Text] [Related]

  • 5. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
    Chang CC, Liang YC, Klutz A, Hsu CI, Lin CF, Mold DE, Chou TC, Lee YC, Huang RC.
    Cancer Chemother Pharmacol; 2006 Nov 12; 58(5):640-53. PubMed ID: 16544145
    [Abstract] [Full Text] [Related]

  • 6. NSC23925, identified in a high-throughput cell-based screen, reverses multidrug resistance.
    Duan Z, Choy E, Hornicek FJ.
    PLoS One; 2009 Oct 12; 4(10):e7415. PubMed ID: 19823672
    [Abstract] [Full Text] [Related]

  • 7. Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors.
    Ho EA, Soo PL, Allen C, Piquette-Miller M.
    J Control Release; 2007 Jan 22; 117(1):20-7. PubMed ID: 17113177
    [Abstract] [Full Text] [Related]

  • 8. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
    George JA, Chen T, Taylor CC.
    Cancer Res; 2005 Nov 15; 65(22):10381-8. PubMed ID: 16288028
    [Abstract] [Full Text] [Related]

  • 9. In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel.
    Zhu X, Sui M, Fan W.
    Anticancer Res; 2005 Nov 15; 25(3B):1953-62. PubMed ID: 16158930
    [Abstract] [Full Text] [Related]

  • 10. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS, Hua J, Gibb RK, Mutch DG, Herzog TJ.
    Gynecol Oncol; 2004 Jul 15; 94(1):67-73. PubMed ID: 15262121
    [Abstract] [Full Text] [Related]

  • 11. MS-209, a quinoline-type reversal agent, potentiates antitumor efficacy of docetaxel in multidrug-resistant solid tumor xenograft models.
    Naito M, Matsuba Y, Sato S, Hirata H, Tsuruo T.
    Clin Cancer Res; 2002 Feb 15; 8(2):582-8. PubMed ID: 11839680
    [Abstract] [Full Text] [Related]

  • 12. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
    Koo JS, Choi WC, Rhee YH, Lee HJ, Lee EO, Ahn KS, Bae HS, Ahn KS, Kang JM, Choi SU, Kim MO, Lu J, Kim SH.
    Life Sci; 2008 Nov 21; 83(21-22):700-8. PubMed ID: 18845169
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1.
    Wu DD, Li XS, Meng XN, Yan J, Zong ZH.
    Tumour Biol; 2016 Aug 21; 37(8):10499-506. PubMed ID: 26850595
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Multidrug resistance reversal agent, NSC77037, identified with a cell-based screening assay.
    Susa M, Choy E, Yang C, Schwab J, Mankin H, Hornicek F, Duan Z.
    J Biomol Screen; 2010 Mar 21; 15(3):287-96. PubMed ID: 20150589
    [Abstract] [Full Text] [Related]

  • 20. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin.
    Mechetner E, Kyshtoobayeva A, Zonis S, Kim H, Stroup R, Garcia R, Parker RJ, Fruehauf JP.
    Clin Cancer Res; 1998 Feb 21; 4(2):389-98. PubMed ID: 9516927
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.